Back to Awarded Treatment Trials


Awarded Trial: 02T-135

Grant ID

02T-135

Illness

Schizophrenia

Primary Drug/Intervention

Buspirone

Primary Dosage

15mg-30mg

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Norman

Sample Size

18

Duration of Study Period for Each Subject

13 weeks

Outcome Measurements

SADS-L, PANSS, SANS, BPRS, AIMS, cognitive battery

Results

Eighteen patients were randomized to buspirone or placebo for 6 wks as adjunct medication. There were no significance differences between the two groups on measures of cognitive function or symptom rating.

Publication

Piskulic D, Olver JS, Maruff P, Norman TR. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT1A receptor agonist. Hum Psychopharmacol. 2009 Aug;24(6):437-46.

Link

http://www.ncbi.nlm.nih.gov/pubmed/19637398

PI Name

Trevor Norman

Degree

PhD

Center

Department of Psychiatry

Institution

University of Melbourne

Address

Austin and Repatriation Medical Centre

City or Town

Heidelberg

State or Province

Victoria

Zip or Postal Code

3084

Country

Australia

Email Address

trevorrn@unimelb.edu.au